Q4 Earnings Estimate for Altimmune Issued By HC Wainwright

Altimmune, Inc. (NASDAQ:ALT) – Stock analysts at HC Wainwright issued their Q4 2027 EPS estimates for Altimmune in a research note issued to investors on Monday, March 16th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings of ($0.30) per share for the quarter. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Altimmune’s current full-year earnings is ($1.35) per share.

ALT has been the subject of several other research reports. William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Altimmune in a research note on Monday, December 29th. Barclays assumed coverage on Altimmune in a report on Tuesday, January 27th. They set an “overweight” rating and a $20.00 price target for the company. B. Riley Financial reduced their price objective on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Finally, Truist Financial initiated coverage on shares of Altimmune in a research report on Wednesday. They issued a “buy” rating and a $12.00 target price on the stock. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Altimmune Trading Down 3.1%

ALT opened at $3.42 on Tuesday. Altimmune has a one year low of $2.90 and a one year high of $7.73. The stock has a market capitalization of $444.84 million, a PE ratio of -3.39 and a beta of 0.13. The business’s 50 day moving average price is $4.46 and its 200 day moving average price is $4.29. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%.

Hedge Funds Weigh In On Altimmune

A number of hedge funds and other institutional investors have recently bought and sold shares of ALT. Geode Capital Management LLC increased its stake in Altimmune by 13.4% during the second quarter. Geode Capital Management LLC now owns 1,934,880 shares of the company’s stock worth $7,489,000 after purchasing an additional 228,995 shares during the period. Brown Wealth Management LLC boosted its stake in shares of Altimmune by 131.0% in the second quarter. Brown Wealth Management LLC now owns 231,083 shares of the company’s stock valued at $894,000 after purchasing an additional 131,059 shares during the period. Intech Investment Management LLC boosted its stake in shares of Altimmune by 102.9% in the second quarter. Intech Investment Management LLC now owns 144,890 shares of the company’s stock valued at $561,000 after purchasing an additional 73,482 shares during the period. Jefferies Financial Group Inc. grew its holdings in shares of Altimmune by 40.0% in the second quarter. Jefferies Financial Group Inc. now owns 35,000 shares of the company’s stock valued at $135,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Altimmune by 43.0% in the second quarter. Steward Partners Investment Advisory LLC now owns 213,384 shares of the company’s stock valued at $826,000 after purchasing an additional 64,175 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CEO Jerome Benedict Durso purchased 20,000 shares of the stock in a transaction dated Friday, March 6th. The stock was acquired at an average cost of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the transaction, the chief executive officer directly owned 32,500 shares in the company, valued at approximately $115,050. This represents a 160.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director John Gill acquired 12,500 shares of the company’s stock in a transaction dated Tuesday, December 23rd. The stock was purchased at an average cost of $4.10 per share, with a total value of $51,250.00. Following the completion of the purchase, the director directly owned 12,500 shares of the company’s stock, valued at approximately $51,250. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders acquired 55,527 shares of company stock worth $213,778. 4.40% of the stock is owned by corporate insiders.

Trending Headlines about Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Truist initiated coverage with a “Buy” and a $12.00 price target (roughly 250% upside vs. current levels), which could attract buyers and improve sentiment. Read More.
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and a $25 price target and raised several near‑term EPS forecasts (Q1–Q4 2026 and FY2026/FY2027 upgrades and smaller quarter‑by‑quarter EPS improvements), signaling improved near‑term operating expectations. Read More.
• Neutral Sentiment: Reported short‑interest entries show a large “increase” but list 0 shares and NaN changes, with days‑to‑cover = 0.0 — this appears to be a data glitch and unlikely to have a clear market effect unless corrected. (No external link available)
• Negative Sentiment: HC Wainwright also trimmed longer‑term forecasts materially (FY2028 and FY2029 EPS were reduced), indicating weaker expected longer‑term profitability; this could limit enthusiasm for the very high $25 PT or lead some investors to remain cautious. Read More.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.